CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Zai Lab Limited - ZLAB CFD

    24.33
    1.93%
    0.22
    Low: 24.28
    High: 24.84
    Market Trading Hours* (UTC) Opens on Monday at 13:30

    Mon - Fri: 13:30 - 20:00

    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.22
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026151 %
    Charges from full value of position ($-4.97)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026151%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003929 %
    Charges from full value of position ($0.75)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003929%
    Overnight fee time 21:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Zai Lab Ltd ESG Risk Ratings

    High Medium Low Negligible

    ‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 23.87
    Open* 24.84
    1-Year Change* -41.98%
    Day's Range* 24.28 - 24.84
    52 wk Range 20.98-53.95
    Average Volume (10 days) 633.99K
    Average Volume (3 months) 10.49M
    Market Cap 2.70B
    P/E Ratio -100.00K
    Shares Outstanding 968.57M
    Revenue 251.80M
    EPS -4.09
    Dividend (Yield %) N/A
    Beta 1.10
    Next Earnings Date Nov 7, 2023

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Sep 22, 2023 24.33 -0.35 -1.42% 24.68 24.84 24.18
    Sep 21, 2023 23.87 -0.44 -1.81% 24.31 24.40 23.68
    Sep 20, 2023 25.27 0.41 1.65% 24.86 25.73 24.86
    Sep 19, 2023 25.24 -0.06 -0.24% 25.30 25.34 24.04
    Sep 18, 2023 25.70 -0.28 -1.08% 25.98 27.71 25.56
    Sep 15, 2023 25.69 0.42 1.66% 25.27 25.92 24.96
    Sep 14, 2023 25.51 0.30 1.19% 25.21 26.42 25.21
    Sep 13, 2023 24.99 -1.49 -5.63% 26.48 26.48 24.92
    Sep 12, 2023 26.42 1.07 4.22% 25.35 26.43 25.35
    Sep 11, 2023 26.38 -0.44 -1.64% 26.82 27.41 25.99
    Sep 8, 2023 26.32 -0.51 -1.90% 26.83 26.98 25.79
    Sep 7, 2023 27.24 0.29 1.08% 26.95 27.84 26.26
    Sep 6, 2023 28.12 0.25 0.90% 27.87 28.17 27.28
    Sep 5, 2023 28.56 -0.06 -0.21% 28.62 28.77 27.93
    Sep 1, 2023 26.00 0.35 1.36% 25.65 26.38 25.49
    Aug 31, 2023 25.36 -0.63 -2.42% 25.99 26.69 25.23
    Aug 30, 2023 26.41 2.31 9.59% 24.10 26.71 24.10
    Aug 29, 2023 23.74 0.96 4.21% 22.78 23.87 22.39
    Aug 28, 2023 22.72 -0.63 -2.70% 23.35 23.63 22.39
    Aug 25, 2023 23.94 -0.14 -0.58% 24.08 24.08 23.35

    Zai Lab Limited Events

    Time (UTC) Country Event
    No events scheduled
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 215.04 144.312 48.958 12.985 0.12945
    Total Operating Expense 619.397 844.376 350.759 216.181 141.898
    Selling/General/Admin. Expenses, Total 258.971 218.831 111.312 70.211 21.5759
    Research & Development 286.408 573.306 222.711 142.221 120.278
    Operating Income -404.357 -700.064 -301.801 -203.196 -141.768
    Interest Income (Expense), Net Non-Operating -41.821 2.19 4.939 7.939 3.22096
    Other, Net 3.113 -5.54 29.076 0.938 0.05878
    Net Income Before Taxes -443.065 -703.414 -267.786 -194.319 -138.488
    Net Income After Taxes -443.065 -703.414 -267.786 -194.319 -138.488
    Net Income Before Extra. Items -443.286 -704.471 -268.905 -195.071 -139.075
    Net Income -443.286 -704.471 -268.905 -195.071 -139.075
    Income Available to Common Excl. Extra. Items -443.286 -704.471 -268.905 -195.071 -139.075
    Income Available to Common Incl. Extra. Items -443.286 -704.471 -268.905 -195.071 -139.075
    Dilution Adjustment
    Diluted Net Income -443.286 -704.471 -268.905 -195.071 -139.075
    Diluted Weighted Average Shares 958.067 929.921 77.6677 64.3695 52.6098
    Diluted EPS Excluding Extraordinary Items -0.46269 -0.75756 -3.46225 -3.03049 -2.64352
    Dividends per Share - Common Stock Primary Issue
    Diluted Normalized EPS -0.46269 -0.75756 -3.46225 -3.03049 -2.64352
    Equity In Affiliates -0.221 -1.057 -1.119 -0.752 -0.58655
    Revenue 215.04 144.312 48.958 12.985 0.12945
    Cost of Revenue, Total 74.018 52.239 16.736 3.749 0.04359
    Gross Profit 141.022 92.073 32.222 9.236 0.08586
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 68.864 62.797 62.601 57.54 48.176
    Revenue 68.864 62.797 62.601 57.54 48.176
    Cost of Revenue, Total 23.763 21.337 20.924 20.044 17.407
    Gross Profit 45.101 41.46 41.677 37.496 30.769
    Total Operating Expense 158.365 132.319 159.894 186.123 146.892
    Selling/General/Admin. Expenses, Total 67.92 62.51 72.024 66.555 63.401
    Research & Development 76.682 48.472 66.946 99.524 66.084
    Operating Income -89.501 -69.522 -97.293 -128.583 -98.716
    Interest Income (Expense), Net Non-Operating -29.989 19.144 -47.056 3.872 1.175
    Other, Net -1.405 1.234 82.58 -36.479 -40.392
    Net Income Before Taxes -120.895 -49.144 -61.769 -161.19 -137.933
    Net Income After Taxes -120.895 -49.144 -61.769 -161.19 -137.933
    Equity In Affiliates 0 0 0 0 0
    Net Income Before Extra. Items -120.895 -49.144 -61.769 -161.19 -137.933
    Net Income -120.895 -49.144 -61.769 -161.19 -137.933
    Income Available to Common Excl. Extra. Items -120.895 -49.144 -61.769 -161.19 -137.933
    Income Available to Common Incl. Extra. Items -120.895 -49.144 -61.769 -161.19 -137.933
    Diluted Net Income -120.895 -49.144 -61.769 -161.19 -137.933
    Diluted Weighted Average Shares 964.817 961.445 959.949 959.086 957.685
    Diluted EPS Excluding Extraordinary Items -0.1253 -0.05111 -0.06435 -0.16807 -0.14403
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.13567 -0.05111 -0.06435 -0.16807 -0.14403
    Unusual Expense (Income) -10
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 1124.34 1500.88 1216.04 292.464 269.144
    Cash and Short Term Investments 1008.47 1409.1 1186.79 275.932 263.302
    Cash 1007.42 663.472 441.283 75.111 36.778
    Cash & Equivalents 1.047 300.628 0.833 0.821 26.1736
    Prepaid Expenses 35.674 18.021 10.935 6.736 5.74926
    Total Assets 1220.14 1609.96 1297.64 355.153 301.987
    Property/Plant/Equipment, Total - Net 77.375 57.291 46.863 36.424 20.4945
    Property/Plant/Equipment, Total - Gross 99.439 73.716 57.115 41.885 22.7024
    Accumulated Depreciation, Total -22.064 -16.425 -10.252 -5.461 -2.20792
    Intangibles, Net 8.403 9.659 9.44 8.803 0.32157
    Long Term Investments 6.431 15.605 1.279 2.398 3.14986
    Note Receivable - Long Term 0 23.858 22.141 13.737 8.04426
    Other Long Term Assets, Total 3.595 2.662 1.879 1.327 0.83259
    Total Current Liabilities 139.842 192.901 98.043 46.635 48.8415
    Accounts Payable 65.974 126.163 62.641 22.66 37.432
    Accrued Expenses 38.739 31.612 18.9 13.941 3.69917
    Notes Payable/Short Term Debt 0 0 0 6.45 3.64262
    Other Current Liabilities, Total 35.129 35.126 16.502 3.584 4.06767
    Total Liabilities 174.545 230 128.293 60.493 50.9054
    Total Long Term Debt 0 0 0 0 0
    Other Liabilities, Total 34.703 37.099 30.25 13.858 2.06394
    Total Equity 1045.59 1379.96 1169.34 294.66 251.082
    Redeemable Preferred Stock
    Common Stock 0.006 0.006 0.005 0.004 0.00348
    Additional Paid-In Capital 2893.12 2825.95 1897.47 734.734 498.043
    Retained Earnings (Accumulated Deficit) -1861.36 -1418.07 -713.603 -444.698 -249.627
    Other Equity, Total 25.685 -23.645 -14.524 4.62 2.66173
    Total Liabilities & Shareholders’ Equity 1220.14 1609.96 1297.64 355.153 301.987
    Total Common Shares Outstanding 960.22 95.4981 87.811 68.2373 49.9126
    Short Term Investments 0 445 744.676 200 200.35
    Total Receivables, Net 48.571 54.809 5.165 3.791 0.08971
    Accounts Receivable - Trade, Net 39.963 47.474 5.165 3.791 0.08971
    Total Inventory 31.621 18.951 13.144 6.005 0.00382
    Treasury Stock - Common -11.856 -4.279
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Total Current Assets 1072.3 1124.34 1209.83 1335.65 1393.25
    Cash and Short Term Investments 930.394 1008.47 1119.48 1256.09 1312.23
    Cash 878.786 1007.42 818.407 381.225 547.259
    Cash & Equivalents 1.058 1.047 301.069 299.595 299.698
    Short Term Investments 50.55 0 0 575.274 465.274
    Total Receivables, Net 60.727 48.571 39.067 38.241 44.242
    Accounts Receivable - Trade, Net 43.346 39.963 27.736 27.054 33.394
    Total Inventory 38.405 31.621 29.131 23.339 20.288
    Prepaid Expenses 42.772 35.674 22.157 17.973 16.49
    Total Assets 1170.07 1220.14 1298.51 1418.78 1500.92
    Property/Plant/Equipment, Total - Net 78.457 77.375 70.797 65.015 62.213
    Property/Plant/Equipment, Total - Gross 102.936 99.439 91.11 84.148 80.461
    Accumulated Depreciation, Total -24.479 -22.064 -20.313 -19.133 -18.248
    Intangibles, Net 8.399 8.403 8.364 8.959 9.519
    Long Term Investments 6.872 6.431 3.316 2.827 8.444
    Note Receivable - Long Term 0 0.006 0.037 20.766
    Other Long Term Assets, Total 4.048 3.595 6.2 6.292 6.722
    Total Current Liabilities 124.56 139.842 155.548 168.877 154.912
    Accounts Payable 66.361 65.974 90.112 108.443 98.161
    Accrued Expenses 18.79 38.739 32.188 25.8 23.113
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 39.409 35.129 33.248 34.634 33.638
    Total Liabilities 168.832 174.545 192.645 206.612 192.907
    Total Long Term Debt 0 0 0 0 0
    Other Liabilities, Total 44.272 34.703 37.097 37.735 37.995
    Total Equity 1001.24 1045.59 1105.87 1212.17 1308.01
    Common Stock 0.006 0.006 0.006 0.006 0.006
    Additional Paid-In Capital 2911.45 2893.12 2877.36 2857.2 2838.66
    Retained Earnings (Accumulated Deficit) -1910.5 -1861.36 -1799.59 -1638.4 -1500.47
    Other Equity, Total 17.272 25.685 39.549 4.487 -25.838
    Total Liabilities & Shareholders’ Equity 1170.07 1220.14 1298.51 1418.78 1500.92
    Total Common Shares Outstanding 963.689 960.22 959.725 958.495 956.637
    Treasury Stock - Common -16.986 -11.856 -11.456 -11.129 -4.347
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -443.286 -704.471 -268.905 -195.071 -139.075
    Cash From Operating Activities -367.642 -549.231 -216.055 -191.011 -97.538
    Cash From Operating Activities 8.227 6.487 4.64 3.766 1.63438
    Amortization 0.0154
    Non-Cash Items 133.187 124.275 29.935 23.577 12.5049
    Changes in Working Capital -65.77 24.478 18.275 -23.283 27.3822
    Cash From Investing Activities 420.016 249.957 -554.83 -14.892 -212.554
    Capital Expenditures -24.984 -18.948 -10.669 -15.242 -10.1178
    Other Investing Cash Flow Items, Total 445 268.905 -544.161 0.35 -202.436
    Cash From Financing Activities -1.73 820.202 1132.44 219.302 144.147
    Issuance (Retirement) of Stock, Net 5.87 824.455 1138.97 216.401 140.504
    Foreign Exchange Effects -6.274 1.116 4.862 0.091 -0.76342
    Net Change in Cash 44.37 522.044 366.417 13.49 -166.709
    Cash Interest Paid 0 0 0.189 0.288 0.0358
    Issuance (Retirement) of Debt, Net 0 0 -6.527 2.901 3.64262
    Financing Cash Flow Items -7.6 -4.253
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -49.144 -443.286 -381.517 -220.327 -82.394
    Cash From Operating Activities -69.287 -367.642 -258.35 -132.027 -87.127
    Cash From Operating Activities 2.657 8.227 6.1 3.874 2.013
    Non-Cash Items 9.255 133.187 134.847 41.836 20.867
    Cash Interest Paid 0
    Changes in Working Capital -32.055 -65.77 -17.78 42.59 -27.613
    Cash From Investing Activities -53.954 420.016 424.389 -143.869 -30.144
    Capital Expenditures -3.516 -24.984 -20.611 -13.595 -9.895
    Other Investing Cash Flow Items, Total -50.438 445 445 -130.274 -20.249
    Cash From Financing Activities -3.886 -1.73 -1.531 -2.24 0.258
    Issuance (Retirement) of Stock, Net 1.197 5.87 5.64 4.619 0.297
    Issuance (Retirement) of Debt, Net 0
    Foreign Exchange Effects -1.299 -6.274 -9.132 -5.144 -0.13
    Net Change in Cash -128.426 44.37 155.376 -283.28 -117.143
    Financing Cash Flow Items -5.083 -7.6 -7.171 -6.859 -0.039
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    Capital World Investors Investment Advisor 5.2849 5223568 557699 2023-06-30 LOW
    Janus Henderson Investors Investment Advisor/Hedge Fund 3.7301 3686754 1815712 2023-06-30 LOW
    Invesco Advisers, Inc. Investment Advisor 3.5809 3539301 -1161245 2023-06-30 LOW
    Viking Global Investors LP Investment Advisor/Hedge Fund 2.6603 2629445 298200 2023-06-30 LOW
    T. Rowe Price Associates, Inc. Investment Advisor 2.6526 2621802 215729 2023-06-30 LOW
    Wellington Management Company, LLP Investment Advisor/Hedge Fund 2.0997 2075352 760307 2023-06-30 LOW
    Segantii Capital Management Limited Hedge Fund 1.8166 1795479 -482796 2023-06-30 HIGH
    Baron Capital Management, Inc. Investment Advisor/Hedge Fund 1.5298 1512061 86847 2023-06-30 LOW
    Fidelity Management & Research Company LLC Investment Advisor 1.5134 1495869 -1175601 2023-06-30 LOW
    Genesis Investment Management, LLP Investment Advisor/Hedge Fund 1.3681 1352222 -217542 2023-06-30 LOW
    Qiming Venture Partners Venture Capital 1.2829 1268000 -6654932 2022-12-31 LOW
    Rock Springs Capital Management LP Hedge Fund 1.2368 1222423 162723 2023-06-30 LOW
    Norges Bank Investment Management (NBIM) Sovereign Wealth Fund 1.0804 1067883 433972 2022-12-31 LOW
    Du (Samantha Ying) Individual Investor 1.0145 1002701 1002701 2023-04-17
    Capital International Investors Investment Advisor 0.9782 966853 250155 2023-06-30 LOW
    Legal & General Investment Management Ltd. Investment Advisor/Hedge Fund 0.9456 934602 161982 2023-06-30 LOW
    Paradigm BioCapital Advisors LP Investment Advisor 0.8755 865297 84739 2023-06-30 LOW
    ClearBridge Investments, LLC Investment Advisor/Hedge Fund 0.8208 811314 15101 2023-06-30 LOW
    SC China Holding Ltd Investment Advisor 0.7028 694634 0 2023-06-30 LOW
    State Street Global Advisors (US) Investment Advisor/Hedge Fund 0.6776 669739 -616150 2023-06-30 LOW

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Zai Lab Limited Company profile

    Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics that address medical needs in the fields of oncology, and autoimmune and infectious disease therapies in the People's Republic of China. Its drug candidates include ZL-2306, a poly ADP ribose polymerase 1/2 inhibitor, which is in Phase III clinical trial for the treatment of ovarian, lung, and breast cancers; ZL-2401, an antibiotic that is in Phase III clinical trial to treat ABSSSI, CABP, and UTI; FPA144, a humanized monoclonal antibody, which is in Phase I/III clinical trial to treat gastric and gastroesophageal cancer; ETX2514, a novel ß-lactamase inhibitor that is in Phase II cUTI trial for the treatment of acinetobacter baumannii; and ZL-2301, which is in Phase III clinical trial to treat HCC. The company's drug candidates also comprise ZL-3101, a novel steroid-sparing topical product that is in Phase II clinical trial for the treatment of eczema and psoriasis; and ZL-2302 to treat non-small cell lung cancer. The company, through its subsidiary, Zai Lab (Shanghai) Co. Ltd., has a collaboration agreement with the NovoCure Limited to perform clinical studies, sell, and import tumor treating field products in the field of oncology. Zai Lab Limited was founded in 2013 and is headquartered in Shanghai, the People's Republic of China.
    Industry: Biopharmaceuticals

    4560 Jinke Road
    Bldg. 1, 4/F
    SHANGHAI
    SHANGHAI 201210
    CN

    Income Statement

    • Annual
    • Quarterly

    News

    EUR/USD tests key support

    EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

    14:32, 21 September 2023
    Bank of England building

    BoE leaves rates unchanged, GBP drops further as investors look for more clarity

    The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

    11:45, 21 September 2023
    British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

    GBP softer after CPI surprise, JPY focused on any further hints from Ueda

    GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

    12:42, 20 September 2023

    How to Trade The Break & Retest

    In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

    11:59, 20 September 2023

    Cable coils near lows ahead of Fed and BoE rate decisions

    It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.

    14:16, 19 September 2023

    FTSE 100 Technical Outlook - 18 September 2023

    In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.

    06:55, 19 September 2023
    View of the City of London’s illuminated financial district skyline at dusk

    Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally

    The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.

    13:46, 15 September 2023

    People also watch

    Oil - Crude

    90.14 Price
    +0.770% 1D Chg, %
    Long position overnight fee 0.0415%
    Short position overnight fee -0.0634%
    Overnight fee time 21:00 (UTC)
    Spread 0.030

    BTC/USD

    26,631.10 Price
    +0.190% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 85.00

    US100

    14,710.90 Price
    +0.190% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0039%
    Overnight fee time 21:00 (UTC)
    Spread 7.0

    XRP/USD

    0.51 Price
    -0.750% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 21:00 (UTC)
    Spread 0.01192

    Still looking for a broker you can trust?

    Join the 555.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading